Abivax (XPAR:ABVX) EV-to-EBIT : -2.27 (As of Dec. 11, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abivax EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Abivax's Enterprise Value is €304.33 Mil. Abivax's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-133.91 Mil. Therefore, Abivax's EV-to-EBIT for today is -2.27.

The historical rank and industry rank for Abivax's EV-to-EBIT or its related term are showing as below:

XPAR:ABVX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.95 Med: -6.75 Max: -1.63
Current: -2.27

During the past 11 years, the highest EV-to-EBIT of Abivax was -1.63. The lowest was -37.95. And the median was -6.75.

XPAR:ABVX's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 9.9 vs XPAR:ABVX: -2.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Abivax's Enterprise Value for the quarter that ended in Dec. 2023 was €412.32 Mil. Abivax's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-133.91 Mil. Abivax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -32.48%.

Abivax EV-to-EBIT Historical Data

The historical data trend for Abivax's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax EV-to-EBIT Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-8.58

-13.05

-11.89

-2.79

-3.08

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-11.89	-	-2.79	-	-3.08

Competitive Comparison of Abivax's EV-to-EBIT

For the Biotechnology subindustry, Abivax's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abivax's EV-to-EBIT falls into.

Abivax EV-to-EBIT Calculation

Abivax's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	304.332	/	-133.914
	=	-2.27

Abivax's current Enterprise Value is €304.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abivax's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-133.91 Mil.

Abivax (XPAR:ABVX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Abivax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-133.914	/	412.32185
	=	-32.48 %

Abivax's Enterprise Value for the quarter that ended in Dec. 2023 was €412.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abivax's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-133.91 Mil.

Abivax EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Abivax's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (XPAR:ABVX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ABVX:USA 0RA9:UK 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.